Abbott (NYSE:ABT) today announced compatibility between its FreeStyle Libre 3 sensor and the mylife Loop from Ypsomed and CamDiab.
Combined, the technologies create a smart, automated process for insulin delivery based on real-time glucose data.
The companies launched their automated insulin delivery (AID) system in Germany. They intend to offer it in additional European countries in 2023.
“Our FreeStyle Libre portfolio is already helping to improve the lives of 4.5 million people around the world who are living with diabetes,” said Jared Watkin, SVP of Abbott’s diabetes care business. “We’re partnering with diabetes and digital health technology leaders like Ypsomed and CamDiab to deliver new innovative solutions that make diabetes care as easy as possible, so people can spend less time worrying about their diabetes and more time living.”
About the collaboration between Abbott, Ypsomed and CamDiab
Ypsomed initially announced authorization for the AID in Germany last month. Abbott, Ypsomed and CamDiab announced a partnership to develop an AID earlier this year. They seek to develop and commercialize the integrated AID system with an initial focus in European countries. It remains unavailable in the U.S.
The companies designed a system for the Ypsomed mylife YpsoPump to combine with the CamDiab mylife CamAPS FX algorithm and FreeStyle Libre 3.
It monitors the user’s glucose levels and automatically adjusts and delivers the right amount of insulin at the right time. This eliminates the guesswork of insulin dosing, helping those with diabetes reach better treatment targets.
“As healthcare providers, one of the biggest challenges of insulin therapy is when glucose levels get dangerously low,” said Dr. Rich Bergenstal, executive director of the International Diabetes Center, HealthPartners Institute in Minneapolis. “Technological innovations, like automated insulin delivery systems, can ease some of that uncertainty by continuously monitoring a person’s glucose levels and delivering the right insulin dosage, which can ultimately improve time in range. And better glucose control reduces diabetes complications.”
Abbott also plans to make FreeStyle Libre interoperable with other leading insulin delivery systems, it said.